AzTrials
AzTrials

Psoriatic ArthritisCARTIZNCT07567378

CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry

An observational study of Psoriatic Arthritis and Osteoarthitis, run by JULIO GRANADOS MONTIEL at 1 site in Mexico.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Psoriatic Arthritis, Osteoarthitis, Knee
What is being tested?
Tirzepatide
Type of treatment
Injection or infusion
How many people
30 participants
Where
1 siteMexico
Study dates
May 2026to May 2029
How long will I take part?
52 Weeks
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or off-label metabolic use) with current or historical documented musculoskeletal manifestation, enrolled across three clinical sites in Mexico City with identical protocol: IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site. The population is deliberately heterogeneous in tirzepatide indication and articular diagnosis to permit stratified analysis across the VAT-articular-cardiac-aging axis.

Who may be able to join

  • 1. Age ≥18 years at the time of informed consent. 2. Currently receiving tirzepatide under an independent clinical indication (type 2 diabetes, insulin resistance, obesity with or without associated metabolic disease, renal protection, metabolic hypertension, or associated off-label metabolic use) prescribed by the treating physician independently of the registry.
  • 3. Presence of at least one objectively documented musculoskeletal manifestation - current or historical - defined as any of: (i) inflammatory arthralgia affecting one or more joints with clinical, imaging, or serological support; (ii) CASPAR-positive psoriatic arthritis; (iii) radiographically documented knee osteoarthritis; (iv) enthesitis on physical examination or ultrasound; (v) documented inflammatory arthropathy of the spine or peripheral joints with a specialist diagnosis.
  • 4. For the retrospective-prospective component: availability of clinical documentation of articular state prior to tirzepatide initiation in the patient's medical record. Documentation may include physical examination notes, imaging, laboratory values, or specialist consultation notes.
  • 5. Signed informed consent for registry enrolment, longitudinal serum biobanking, HLA typing at INCMNSZ, quantitative knee MRI with T2 mapping at Ci3M UAM-Iztapalapa at Week 0 and Week 52, non-contrast cardiac CT at INCar at Week 0 and Week 52, multi-frequency bioelectrical impedance analysis at Universidad La Salle México at six timepoints, and (where applicable) medical record review. Each attestation is consented modularly within a single document.
  • 6. Clinical plan to continue tirzepatide for at least 52 weeks from registry Week 0, based on the treating physician's evaluation of current clinical indication. Discontinuation during follow-up is captured as an outcome variable and does not remove the patient from the registry.
  • 7. Capacity to attend scheduled follow-up visits and to undergo bilateral knee MRI at Ci3M (without severe claustrophobia requiring sedation, without absolute contraindication to MRI - see Exclusion 6) and non-contrast cardiac CT at INCar (without uncontrolled arrhythmia precluding ECG-gated imaging of diagnostic quality).
Show all 9Show fewer
  • For the Surgical Tissue Subcohort (Cohort 3) only - additional criteria applied at the time of subcohort enrolment:
  • 8s. Scheduled clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez (coronary artery bypass grafting, valve replacement, or combined procedures) during registry follow-up.
  • 9s. Specific additional informed consent for intraoperative collection of epicardial adipose tissue fragments.

Who cannot join

  • 1. Initiation or modification of a biologic disease-modifying antirheumatic drug (biologic DMARD) or JAK inhibitor within the 12 weeks prior to Week 0, or clinically anticipated initiation or modification during the first 12 weeks of follow-up. Washout may permit re-screening.
  • 2. Major joint surgery within the 3 months prior to Week 0, or planned major joint surgery within the 12 months following Week 0, involving any joint scheduled for evaluation in the registry.
  • 3. Intra-articular corticosteroid or hyaluronic acid injection within the 6 weeks prior to baseline biospecimen collection in any joint. Patients beyond the 6-week washout are eligible.
  • 4. Active malignancy, with the exception of adequately treated non-melanoma skin carcinoma. History of malignancy in remission ≥5 years is permitted at the discretion of the treating investigator.
  • 5. Current pregnancy, lactation, or planned pregnancy within the 12-month observation period.
  • 6. Absolute contraindication to MRI, including non-MRI-compatible cardiac pacemaker or implanted defibrillator, ferromagnetic intracranial vascular clips, non-documented non-MRI-compatible cochlear implants, or other contraindication per the local MRI safety protocol.
Show all 11Show fewer
  • 7. Systemic rheumatologic disease other than psoriatic arthritis or osteoarthritis requiring active immunomodulation, specifically: seropositive rheumatoid arthritis on biologic therapy, active systemic lupus erythematosus on immunomodulation, active vasculitis on immunosuppression, or other systemic disease whose treatment confounds the inflammatory axis the registry is designed to characterize.
  • 8. Inability to provide informed consent (cognitive impairment, language barrier not resolvable with site interpreter, or other incapacity to understand the protocol), or anticipated inability to complete the 52-week follow-up.
  • For the Surgical Tissue Subcohort (Cohort 3) only - additional exclusions:
  • 9s. Prior major cardiac surgery resulting in extensive pericardial adhesions that preclude safe intraoperative EAT fragment collection, as assessed by the operating cardiac surgeon.
  • 10s. Emergency cardiac surgery precluding the specific informed consent process.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Julio Granados-Montiel, MD, PhD contact

+52 5554329237

juliogram@gmail.com

Marwin Gutiérrez, MD contact

Mexico1 site

  • IMSS Clínica Río Magdalena

    Mexico City, Mexico City, 01090

    Julio Granados-Montiel, MD, PhD, +52 5554329237, juliogram@gmail.com

Other trials in Mexico

About this study

Official title: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts (CARTIZ): A Prospective Observational Multi-Institutional Registry of the VAT-Articular-Cardiac-Aging Axis in Adults Exposed to Tirzepatide in Mexico, With Quantitative Knee Cartilage T2 Mapping, Cardiac CT Epicardial Adipose Tissue Radiomic Phenotyping, HLA Stratification, Longitudinal Multi-Frequency Bioimpedance Body Composition, and a Prespecified Surgical Tissue Acquisition Subcohort

CARTIZ is a prospective observational clinical registry of adults in Mexico receiving tirzepatide (a dual GLP-1/GIP receptor agonist) under an independent clinical indication - typically type 2 diabetes, insulin resistance, obesity, renal protection, metabolic hypertension, or associated off-label metabolic use. The registry is entirely observational: CARTIZ does not initiate, modify, interrupt, or supply tirzepatide, and does not dictate dose, route, or duration. All pharmacological exposure decisions are made by the treating physician independently of study participation. The registry is operationalized through a four-institute architecture integrating three Mexican National Institutes of Health and one national imaging laboratory. Core 1 (Knee Cartilage Imaging, Ci3M UAM-Iztapalapa) performs bilateral 3T MRI with quantitative T2 mapping at Week 0 and Week 52. Core 2 (Cardiac Imaging, Instituto Nacional de Cardiología Ignacio Chávez) performs non-contrast cardiac computed tomography for radiomic phenotyping of epicardial adipose tissue at Week 0 and Week 52 under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas. Core 3 (HLA Typing, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Transplant Department) performs Class I and Class II HLA typing by PCR-SSO Reverse Luminex. Core 4 (Body Composition, Universidad La Salle México) performs multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints capturing visceral adipose tissue trajectory, phase-angle trajectory, appendicular skeletal muscle mass, and hydration ratios at zero marginal cost. The registry enrolls n=30 patients across three clinical sites with identical protocol (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, and a private practice site in Mexico City), generating 60 evaluable knees and 30 paired cardiac CT studies. The primary co-endpoints address a mechanistic question no other tirzepatide study is positioned to answer: whether the articular response to tirzepatide in inflammatory arthropathy precedes and mechanistically precedes weight loss, through formal mediation analysis of Week-4 ACR20 response via high-sensitivity C-reactive protein, SERPINB2, and dipeptidyl peptidase-4 activity, restricted to the Mechanistic Analysis Set of patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI <1.0 kg/m² through Week 4. A prespecified Surgical Tissue Subcohort is declared at initial registration to establish public scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP/GLP-1 receptor agonism. Subcohort participants who undergo clinically indicated cardiac surgery at INCar during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) are invited to provide specific additional informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access and otherwise discarded as surgical waste. Operational launch is contingent on separate INCar tissue-specific approvals and will proceed via PRS record amendment when ready

Read the detailed description

Background and rationale. Tirzepatide, a dual agonist of the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors, has demonstrated unprecedented cardiometabolic potency in registration trials (SURPASS, SURMOUNT, SYNERGY-NASH, SUMMIT). Recent evidence has extended the mechanistic reach of the molecule beyond glycemia and weight to specific tissue compartments. The SUMMIT cardiac magnetic resonance substudy demonstrated reduction of left ventricular mass and paracardiac adipose tissue at 52 weeks in heart failure with preserved ejection fraction with obesity. A prespecified diabetes-stratification analysis of SUMMIT established that these structural effects are partially independent of weight change. The SURPASS cardiovascular outcomes trial established cardiovascular superiority of tirzepatide over GLP-1 monoagonism. A recent randomized clinical trial in psoriatic arthritis with overweight or obesity demonstrated articular response at Week 4 when dual incretin agonism was added to IL-17A inhibition, prior to substantial weight loss. The "multi-nutrient-stimulated-hormone" (multi-NuSH) framework now organizing the field articulates the conceptual reach of dual and multi-incretin agonism beyond glycemia. Mechanistic work on human and murine adipocytes establishes direct GIP receptor effects on visceral adipose depots that are biologically distinct from weight-mediated effects. Bibliographic support for each of these statements is provided in the Citations field of this record.

The Mexican off-label access asset. Access to tirzepatide in the United States and Europe is restricted by payer prior-authorization to narrow on-label indications. In Mexico, out-of-pocket access permits a phenotypic breadth of clinical exposure not replicable in sponsor-led trials, including patients who receive tirzepatide for insulin resistance, metabolic hypertension, renal protection, and off-label metabolic indications. This pharmacological natural experiment allows the registry to capture the articular, cardiac, compositional, and aging-biology response to dual GIP/GLP-1 agonism across a clinical breadth sponsor trials cannot access. The window is finite: as label expansion advances, the uniqueness of Mexican off-label exposure attenuates. The registry is positioned to capture this window.

Four-institute architecture. CARTIZ operates through four specialized cores, each led by a qualified investigator at an independent institution, producing endpoints of differentiated resolution and relevance.

Core 1 - Knee Cartilage Imaging Core (Level 3A). Bilateral 3T knee MRI with quantitative T2 mapping at Week 0 and Week 52, performed at Ci3M UAM-Iztapalapa (CONACYT National Laboratory) under Dr. Andres Moron and Dr. Luis Jimenez Angelez departamento de ingenieria en sistemas biomedicos, Facultad de Ingenieria UNAM. All imaging at a single Philips 3T platform with harmonized pulse-sequence parameters. Central overread. 60 evaluable knees at n=30.

Core 2 - Cardiac Imaging Core (Level 3B). Non-contrast cardiac computed tomography with prospective electrocardiographic gating at Week 0 and Week 52, performed at the Instituto Nacional de Cardiología Ignacio Chávez under cardiovascular Co-Principal Investigator Dr. Erick Alexánderson Rosas, Chief of the Departamento de Cardiología Nuclear e Imagen Cardiovascular Molecular. Radiomic phenotyping of epicardial adipose tissue (EAT) following the Imaging Biomarker Standardization Initiative (IBSI) specifications using PyRadiomics, with quantification of EAT volume, mean attenuation (Hounsfield units), attenuation distribution (standard deviation, skewness, kurtosis), and texture features (first-order, gray-level co-occurrence matrix, gray-level run-length matrix, gray-level size-zone matrix, neighborhood gray-tone difference matrix). Fat Attenuation Index (FAI) quantification in the adventitia of proximal left anterior descending, circumflex, and right coronary artery territories per published perivascular FAI methodology. 30 paired cardiac CT studies.

Core 3 - HLA Typing Core (Level 2). Class I (A, B, C) and Class II (DRB1, DQB1, DPB1) HLA typing by PCR-SSO Reverse Luminex at the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ) Transplant Department under Dr. Mario Vilatoba. Anonymized archival for population comparison and kinship-linkage analysis.

Core 4 - Body Composition Core (Level 4). Multi-frequency bioelectrical impedance analysis (seca mBCA) at six longitudinal timepoints (Week 0, 2, 4, 12, 24, 52) at Universidad La Salle México, capturing visceral adipose tissue trajectory, phase-angle trajectory (an established aging-biology biomarker), appendicular skeletal muscle mass, total body water, extracellular water, and hydration ratios. Available at zero marginal cost to the registry.

Five-level endpoint structure. Endpoints are organized in five levels of differentiated resolution: Level 1 - mechanistic deconvolution (PI-executed, primary); Level 2 - biomarker and HLA stratification (sponsor-executed under MTA, hypothesis-generating); Level 3A - knee structural imaging (Ci3M, PI-executed); Level 3B - cardiac structural imaging (INCar, PI-executed); and Level 4 - body composition and aging biology (La Salle, PI-executed).

Primary co-endpoints. (1) ACR20 response rate at Week 4 in the Mechanistic Analysis Set (MAS), defined as patients with tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI <1.0 kg/m² through Week 4. (2) Proportion of Week-4 ACR20 response mediated by the combined biomarker panel (high-sensitivity C-reactive protein, SERPINB2, dipeptidyl peptidase-4 activity) in the MAS, assessed by the MacKinnon product-of-coefficients method with 10,000 bias-corrected and accelerated bootstrap iterations.

Surgical Tissue Subcohort (prespecified secondary arm). A subset of enrolled participants who undergo clinically indicated cardiac surgery at INCar during registry follow-up (coronary artery bypass grafting, valve replacement, or combined procedures) will be invited to provide specific informed consent for collection of epicardial adipose tissue fragments routinely excised during operative access to the heart (e.g., during aortic root exposure for AVR, coronary target exposure for CABG, or mitral annular exposure for MVR). These fragments are ordinarily discarded as surgical waste. Under this subcohort they are collected intraoperatively, divided into fresh-frozen aliquots (RNAlater, OCT) and formalin-fixed aliquots (10% neutral-buffered formalin), and processed for bulk and/or single-nucleus RNA sequencing, histological characterization, and biobanking for prespecified future analyses. Tissue acquisition does not modify the surgical procedure. Operational launch is contingent on favorable opinion of the INCar Comité de Investigación and Comité de Ética en Investigación for the tissue-specific protocol, formal operational agreement with the INCar Servicio de Cirugía Cardiovascular, and PRS record amendment. This subcohort is declared at initial registration to establish scientific priority for direct human epicardial adipose tissue transcriptomic characterization under dual GIP/GLP-1 receptor agonism - a gap explicitly identified in the multi-NuSH framework and not filled by any currently published or registered study.

Governance and oversight. Independent Scientific Advisory Board (ISAB) with advisory competence over the Statistical Analysis Plan, publication policy, and database lock. Cryptographic provenance infrastructure: SHA-256 hash chain for every biospecimen manifest entry, every DICOM series, and every database snapshot, anchored to an append-only audit log under version control, with three-server email timestamping. Informed consent is modular: each attestation (prospective participation, serum biobanking, HLA typing, knee MRI, cardiac CT, body composition, medical record review, and - for the surgical subcohort - tissue collection) is consented separately within a single document. All data transferred to sponsors is de-identified to HIPAA Safe Harbor and LFPDPPP Mexican standards, with cryptographic separation between re-identification key and transferred dataset.

Intellectual property status. Four United States Provisional Patent Applications are active, filed pro se by the Principal Investigator as micro entity: PROV-001 (64/019,134, 27 March 2026, DPP4-Incretin-SERPIN axis for chondroprotection); PROV-002 (64/031,635, 7 April 2026, BMP/ROCK/DPP4/Mechanosensory axis); PROV-003 (64/039,918, 15 April 2026, cartilage companion biomarkers); PROV-004 (64/043,606, 19 April 2026, HLA-guided GIPR companion diagnostics). All four are referenced as Secondary IDs in this registration.

Being tested
Tirzepatide
Keywords
Tirzepatide, Dual GIP/GLP-1 receptor agonist, Multi-nutrient-stimulated hormones, Psoriatic arthritis, Inflammatory arthropathy, ACR20, Cartilage T2 mapping, Quantitative knee MRI, Epicardial adipose tissue, Cardiac CT radiomics, Fat Attenuation Index, HLA typing, Visceral adipose tissue, Phase angle, seca mBCA, Bioelectrical impedance analysis, Mediation analysis, Weight-independent effect, Off-label exposure, Mexican registry
Medical subject headings
Arthritis, Psoriatic, Diabetes Mellitus, Diabetes Mellitus, Type 2, Obesity, Metabolic Syndrome, Heart Failure, Coronary Artery Disease, Atrial Fibrillation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TirzepatideDrug

    Dual GLP-1 and GIP receptor agonist administered subcutaneously at doses and intervals determined by the treating physician independently of this registry. The registry does not supply, initiate, modify, or discontinue tirzepatide; exposure is documented from the medical record and patient report.

Study groups in NCT07567378
Study groupRoleWhat they receive
Retrospective-ProspectivePatients currently under the Principal Investigator's care who are already receiving tirzepatide for an independent clinical indication at the time of registry enrolment, with pre-tirzepatide articular, metabolic, and clinical documentation available in the medical record. Baseline pre-tirzepatide state is reconstructed retrospectively from structured medical record review under a specific informed consent attestation; Week-0 biospecimen and imaging acquisition is prospective. Expected n=10-20 from the Principal Investigator's existing patient pool. Recruitment Status: Not yet recruiting.
Receives: Drug: Tirzepatide
Fully ProspectivePatients identified across the three clinical sites (IMSS Clínica Río Magdalena, INCMNSZ outpatient clinic, private practice in Mexico City) who are initiating tirzepatide under an independent clinical indication during the registry enrolment window, enrolled at or before Week 0 of tirzepatide exposure. Protocol is identical to Cohort 1 from Week 0 forward; the difference is the absence of pre-tirzepatide retrospective reconstruction. Expected n=10-20 recruited over 6-12 months. Recruitment Status: Not yet recruiting.
Receives: Drug: Tirzepatide
Surgical Tissue SubcohortSubset of enrolled Cohort 1 or Cohort 2 participants undergoing clinically indicated cardiac surgery at the Instituto Nacional de Cardiología Ignacio Chávez during follow-up (coronary artery bypass grafting, valve replacement, or combined procedures), providing additional informed consent for intraoperative collection of epicardial adipose tissue fragments routinely excised during cardiac access and discarded as surgical waste. Tissue acquisition does not modify the surgical procedure. This subcohort is declared at initial registration to establish scientific priority on direct human epicardial adipose tissue transcriptomic characterization under dual GIP/GLP-1 receptor agonism. Operational launch requires (a) favorable opinion of INCar Comité de Investigación and Comité de Ética en Investigación for the tissue-specific protocol, (b) formal agreement with INCar Servicio de Cirugía Cardiovascular, (c) PRS amendment reflecting operational launch. Recruitment Status: Not yet recruiting.
Receives: Drug: Tirzepatide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ACR20 response rate at Week 4 in the Mechanistic Analysis Set

    Proportion of patients in the Mechanistic Analysis Set (tirzepatide exposure ≤16 weeks at Week 0 and delta-BMI <1.0 kg/m² through Week 4) achieving ACR20 response (American College of Rheumatology 20% improvement criteria) at Week 4, assessed by standardized clinical evaluation.

    Measured: week 4

  2. Proportion of Week-4 ACR20 response mediated by biomarker panel in the Mechanistic Analysis Set

    Proportion of the Week-4 ACR20 response mediated by the combined biomarker panel (high-sensitivity C-reactive protein, SERPINB2, dipeptidyl peptidase-4 activity) in the Mechanistic Analysis Set, assessed by the MacKinnon product-of-coefficients method with 10,000 bias-corrected and accelerated (BCa) bootstrap iterations. Decision thresholds are prespecified in the Statistical Analysis Plan.

    Measured: Week 4

Secondary outcomes (12)

  1. Change in knee cartilage T2 relaxation time from Week 0 to Week 52

    Change in femoro-tibial and patellar cartilage T2 relaxation time from Week 0 to Week 52, bilateral knees, stratified by zone (medial femur, lateral femur, medial tibia, lateral tibia, patella), analyzed at Ci3M UAM-Iztapalapa on Philips 3T platform. Primary analysis: linear mixed-effects model with random intercepts for patient and for knee-within-patient.

    Measured: Week 0 and week 52

  2. Change in epicardial adipose tissue volume from Week 0 to Week 52

    Change in epicardial adipose tissue (EAT) volume from Week 0 to Week 52 by non-contrast cardiac CT with prospective ECG gating at the Instituto Nacional de Cardiología Ignacio Chávez. Primary analysis: linear mixed-effects model adjusted for baseline EAT volume, age, sex, and baseline BMI. Unit of Measure: milliliters (mL)

    Measured: week 0 and week 52

  3. Change in epicardial adipose tissue mean attenuation from Week 0 to Week 52

    Change in epicardial adipose tissue (EAT) mean attenuation from Week 0 to Week 52 on the same non-contrast cardiac CT acquisitions at the Instituto Nacional de Cardiología Ignacio Chávez. Primary analysis: linear mixed-effects model adjusted for baseline EAT mean attenuation, age, sex, and baseline BMI. Units of Measure: Hounsfield units (HU)

    Measured: week 0 and week 52

  4. Change in epicardial adipose tissue radiomic texture composite z-score from Week 0 to Week 52

    Change in a prespecified compact radiomic signature derived from up to five IBSI-standardized texture features (first-order, GLCM, GLRLM, GLSZM, NGTDM families) computed on non-contrast cardiac CT EAT segmentations and expressed as a normalized composite z-score, from Week 0 to Week 52. Primary analysis: linear mixed-effects model adjusted for baseline composite z-score, age, sex, and baseline BMI. Units of Measure: z-score (dimensionless)

    Measured: week 0 and week 52

  5. Longitudinal visceral adipose tissue trajectory over six timepoints

    Visceral adipose tissue (VAT) volume by seca multi-frequency bioelectrical impedance analysis at Week 0, 2, 4, 12, 24, and 52 at Universidad La Salle México. Trajectory analyzed by linear mixed-effects model with random intercepts and slopes per patient.

    Measured: week 0 through week 52

  6. Longitudinal phase-angle trajectory (aging biomarker) over six timepoints

    Bioimpedance phase angle (an established aging-biology biomarker) measured by seca mBCA at the six longitudinal timepoints. Trajectory and slope modeled per patient and stratified by baseline age tercile.

    Measured: week 0 through week 52

  7. HLA-stratified articular and cardiac response

    ACR20 response at Week 4 and EAT radiomic change at Week 52 stratified by HLA Class I and Class II allele-group profile (INCMNSZ Transplant Department PCR-SSO Reverse Luminex typing). Hypothesis-generating.

    Measured: week 4 and week 52

  8. Change in Leeds Enthesitis Index (LEI) from Week 0 to Week 52 in the psoriatic arthritis subgroup

    Change in LEI score (range 0-6, one point per tender enthesis at six prespecified entheseal sites) from Week 0 to Week 52 in the subgroup with CASPAR-positive psoriatic arthritis. Higher score indicates greater number of tender entheses. Primary analysis: paired t-test or Wilcoxon signed-rank within subgroup. Unit of Measure: score on a 0-6 scale (LEI)

    Measured: week 0 and week 52

  9. Change in Madrid Sonographic Enthesitis Index (MASEI) from Week 0 to Week 52 in the psoriatic arthritis subgroup

    Change in MASEI score (range 0-136, sonographic assessment of six bilateral entheseal sites for elementary lesions and complications) from Week 0 to Week 52 in the subgroup with CASPAR-positive psoriatic arthritis. Higher score indicates greater sonographic enthesitis burden. Primary analysis: paired t-test or Wilcoxon signed-rank within subgroup. Unit of Measure: score on a 0-136 scale (MASEI)

    Measured: week 0 and week 52

  10. Transcriptomic signature of epicardial adipose tissue in tirzepatide-exposed participants undergoing cardiac surgery

    Bulk and/or single-nucleus RNA sequencing of epicardial adipose tissue fragments collected intraoperatively during clinically indicated cardiac surgery (coronary artery bypass grafting, valve replacement, or combined procedures) at the Instituto Nacional de Cardiología Ignacio Chávez. Differential gene expression and cell-type-resolved transcriptomic analysis compared between tirzepatide-exposed participants and matched non-exposed comparators. Prespecified secondary analyses include correlation of tissue transcriptomic signature with radiomic EAT phenotype and HLA profile in the same participants.

    Measured: At time of cardiac surgery, occurring within 36 months of enrolment

  11. Longitudinal biomarker panel trajectories

    Longitudinal trajectories of high-sensitivity C-reactive protein, SERPINB2, dipeptidyl peptidase-4 activity, and related incretin-axis biomarkers measured in banked serum aliquots at the six longitudinal timepoints. Analyzed per patient and stratified by HLA profile.

    Measured: week 0 through week 52

  12. Change in modified Nail Psoriasis Severity Index (mNAPSI) from Week 0 to Week 52 in the psoriatic arthritis subgroup

    Change in dermoscopy-graded modified Nail Psoriasis Severity Index (mNAPSI; range 0-130 if all 20 nails assessed) from Week 0 to Week 52 in the subgroup with CASPAR-positive psoriatic arthritis. Higher score indicates greater nail involvement. Primary analysis: paired t-test or Wilcoxon signed-rank within subgroup.

    Unit of Measure. score on a mNAPSI scale.

    Measured: Time Frame. Week 0 and Week 52.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2026
  2. Study startMay 2026 (estimated)
  3. Primary completionNov 2027 (estimated)
  4. Study completionMay 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30 participants (estimated)
Target duration
52 Weeks
IDs, dates and publications
ClinicalTrials.gov ID
NCT07567378
Sponsor's protocol ID
CARTIZ-2026-001
Other IDs
CARTIZ-2026-001, 64/019,134, 64/031,635, 64/039,918, 64/043,606
Acronym
CARTIZ
Status last verified
May 2026
First submitted
21 Apr 2026
Last updated
12 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified individual participant data (clinical, imaging, laboratory, biomarker, and - in the Surgical Tissue Subcohort - transcriptomic) will be available for sharing under the registry's predefined Sponsor Access Framework (SAF v2.0). The framework defines four access tiers: T1 Mutual Non-Disclosure Agreement for scientific evaluation discussions; T2 Material Transfer Agreement + Data Use Agreement for serum aliquot transfer and baseline CRF access; T3 Option Agreement on provisional patent applications with longitudinal CRF, DICOM archive, and biomarker dataset access; T4 License + Co-Financing Agreement with full intellectual property license and registry expansion co-financing. All data transferred under any tier is de-identified to HIPAA Safe Harbor and LFPDPPP Mexican standards.

Publications

  • Granados-Montiel J, et al. SERPINB2 as a chondrogenic lineage marker. bioRxiv 2026. doi:10.64898/2026.03.29.713197

  • Yu J, Hou M, Deng Y, Yu C, Liu Y, Kang K, Xia X, Li X, Yang H, Jiang D, Xu W, Zhang Y, Zhu X. Double-Pronged NAD Preservation: Delaying Cellular Senescence and Initiating Musculoskeletal Regeneration. Aging Cell. 2026 Apr;25(4):e70468. doi: 10.1111/acel.70468.

    PubMed 41944220

  • Zwanenburg A, Vallieres M, Abdalah MA, Aerts HJWL, Andrearczyk V, Apte A, Ashrafinia S, Bakas S, Beukinga RJ, Boellaard R, Bogowicz M, Boldrini L, Buvat I, Cook GJR, Davatzikos C, Depeursinge A, Desseroit MC, Dinapoli N, Dinh CV, Echegaray S, El Naqa I, Fedorov AY, Gatta R, Gillies RJ, Goh V, Gotz M, Guckenberger M, Ha SM, Hatt M, Isensee F, Lambin P, Leger S, Leijenaar RTH, Lenkowicz J, Lippert F, Losnegard A, Maier-Hein KH, Morin O, Muller H, Napel S, Nioche C, Orlhac F, Pati S, Pfaehler EAG, Rahmim A, Rao AUK, Scherer J, Siddique MM, Sijtsema NM, Socarras Fernandez J, Spezi E, Steenbakkers RJHM, Tanadini-Lang S, Thorwarth D, Troost EGC, Upadhaya T, Valentini V, van Dijk LV, van Griethuysen J, van Velden FHP, Whybra P, Richter C, Lock S. The Image Biomarker Standardization Initiative: Standardized Quantitative Radiomics for High-Throughput Image-based Phenotyping. Radiology. 2020 May;295(2):328-338. doi: 10.1148/radiol.2020191145. Epub 2020 Mar 10.

    PubMed 32154773

  • Oikonomou EK, Marwan M, Desai MY, Mancio J, Alashi A, Hutt Centeno E, Thomas S, Herdman L, Kotanidis CP, Thomas KE, Griffin BP, Flamm SD, Antonopoulos AS, Shirodaria C, Sabharwal N, Deanfield J, Neubauer S, Hopewell JC, Channon KM, Achenbach S, Antoniades C. Non-invasive detection of coronary inflammation using computed tomography and prediction of residual cardiovascular risk (the CRISP CT study): a post-hoc analysis of prospective outcome data. Lancet. 2018 Sep 15;392(10151):929-939. doi: 10.1016/S0140-6736(18)31114-0. Epub 2018 Aug 28.

    PubMed 30170852

  • Antonopoulos AS, Sanna F, Sabharwal N, Thomas S, Oikonomou EK, Herdman L, Margaritis M, Shirodaria C, Kampoli AM, Akoumianakis I, Petrou M, Sayeed R, Krasopoulos G, Psarros C, Ciccone P, Brophy CM, Digby J, Kelion A, Uberoi R, Anthony S, Alexopoulos N, Tousoulis D, Achenbach S, Neubauer S, Channon KM, Antoniades C. Detecting human coronary inflammation by imaging perivascular fat. Sci Transl Med. 2017 Jul 12;9(398):eaal2658. doi: 10.1126/scitranslmed.aal2658.

    PubMed 28701474

  • Qin H, Yu J, Yu H, Zhou C, Yuan D, Wang Z, Zhu Z, Wei G, Ou P, Li Z, Jiang H, Shen J, Xiao G, Bai X, Wang H, Zhang HT, Speakman JR, Chen D, Tong L. Semaglutide ameliorates osteoarthritis progression through a weight loss-independent metabolic restoration mechanism. Cell Metab. 2026 Mar 3;38(3):582-597.e6. doi: 10.1016/j.cmet.2026.01.008. Epub 2026 Feb 9.

    PubMed 41666927

  • Regmi A, Aihara E, Christe ME, Varga G, Beyer TP, Ruan X, Beebe E, O'Farrell LS, Bellinger MA, Austin AK, Lin Y, Hu H, Konkol DL, Wojnicki S, Holland AK, Friedrich JL, Brown RA, Estelle AS, Badger HS, Gaidosh GS, Kooijman S, Rensen PCN, Coskun T, Thomas MK, Roell W. Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor. Cell Metab. 2024 Jul 2;36(7):1534-1549.e7. doi: 10.1016/j.cmet.2024.05.010. Epub 2024 Jun 14.

    PubMed 38878772

  • Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martinez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A. Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134. Online ahead of print.

    PubMed 41903163

  • Meyhofer SM, Cariou B, Cercato C, Colhoun HM, Deanfield J, Long MT, Jeppesen OK, Lincoff AM, Lingvay I, Plutzky J, Newsome PN, Nicholls SJ, Quiroga M, Santini F, Sanyal AJ, Kahn SE; SELECT Trial Investigators. Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial. Nat Med. 2026 May;32(5):1686-1693. doi: 10.1038/s41591-026-04281-1. Epub 2026 Apr 2.

    PubMed 41928037

  • Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, Lincoff AM, McGuire DK, Miller D, Nauck MA, Nishiyama H, Nissen SE, Sattar N, Weerakkody G, Wiese RJ, Zinman B, Zoungas S, Basile J, Davies MJ, Giorgino F, Kellerer M, Ji L, Varkonyi T, Menon V, Broder JC, Herschtal A, D'Alessio D; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025 Dec 18;393(24):2409-2420. doi: 10.1056/NEJMoa2505928.

    PubMed 41406444

  • Packer M, Zile MR, Kramer CM, DiMaria JM, Baum SJ, Litwin SE, Murakami M, Zhou C, Ou Y, Koeneman L, Borlaug BA; SUMMIT Trial Study Group. Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis. J Am Coll Cardiol. 2025 Sep 9;86(10):696-707. doi: 10.1016/j.jacc.2025.06.058.

    PubMed 40903131

  • Kang YM, Harrington J, Aroda VR, McGuire DK. Beyond GLP1: modulating multiple nutrient-stimulated hormone pathways to reduce cardiovascular risk. Nat Rev Cardiol. 2026 Jul;23(7):449-451. doi: 10.1038/s41569-026-01296-6. No abstract available.

    PubMed 42010357

  • Kramer CM, Borlaug BA, Zile MR, Ruff D, DiMaria JM, Menon V, Ou Y, Zarante AM, Hurt KC, Murakami M, Packer M; SUMMIT Trial Study Group. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy. J Am Coll Cardiol. 2025 Feb 25;85(7):699-706. doi: 10.1016/j.jacc.2024.11.001. Epub 2024 Nov 18.

    PubMed 39566869

Questions about this trial

What is this clinical trial studying?

An observational study of Psoriatic Arthritis and Osteoarthitis, run by JULIO GRANADOS MONTIEL at 1 site in Mexico.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 12 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Julio Granados-Montiel, MD, PhD (+52 5554329237, juliogram@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ACR20 response rate at Week 4 in the Mechanistic Analysis Set (time frame: week 4). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07567378, which also lists 13 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 May 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in